08 17 21 -- 10 Critical Validation Parameters For Microbiological Experiments pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
01.21.21 Using Production And Postmarket Data To Validate FMEA Assumptions
Acepodia s Dr. Sony Hsiao, CEO, and Dr. Mark Gilbert, SVP of R&D, join
Business of Biotech for a discussion on the company s approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates. Listen now and subscribe so you never miss an episode.
Featured Editorial
By Mark Durivage, Quality Systems Compliance LLC
One common issue with regulatory agencies and certification bodies regarding failure mode and effects analysis (FMEA) is that organizations are not utilizing production and post-market surveillance data to validate the probability of occurrence and probability of detection assumptions, which leads to inspectional observations and audit findings.
Upstream Considerations For Biosimilar Development
By Hunter Malanson, Staff Scientist, Field Applications; Mariana Curcio, Technical Sales Specialist; and Albert Cheong, Associate Director, Services & Product Application, Thermo Fisher Scientific Bioproduction Cell Culture
Many of the early and costly steps of drug development can be eliminated with biosimilars, which offer several advantages to pharmaceutical companies exploring new strategies for increasing their presence in the market. However, essential information regarding aspects of process control, such as upstream control parameters, may be unknown about the innovator drug, resulting in challenges during biosimilar development. Understanding these challenges and creating a strategy to overcome them is critical for ensuring a high chance of success with your biosimilar product.